Bispecific antibodies targeting pathology, such as anti-Aβ/anti-tau, reduced pathology by 30% in 3xTg-AD mice; however, glycoengineering is necessary to mitigate immunogenicity risks [129]. Here, MAPT is linked to Alzheimer disease.